Alector Therapeutics, working with AbbVie, was testing whether modulating immune cells in brain would slow Alzheimer's ...
Shares of Alector tumbled in after-hours trading after the company said its Alzheimer drug candidate, AL002, failed to meet its phase 2 primary endpoint of slowing clinical progression of the disease.
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment ...
Alector reported a Phase 2 failure for an AbbVie-partnered Alzheimer’s program Monday afternoon and said it will ...
Alector ( (ALEC) ) has released its Q3 earnings. Here is a breakdown of the information Alector presented to its investors.Don't Miss our Black ...
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology ...
Neurogene shares tumbled 35% last night after it disclosed that a pediatric patient with Rett syndrome experienced a severe ...
Alector ( (ALEC)) has provided an update. Alector, a clinical-stage biotechnology company, has secured a $50 million credit facility from Hercules Capital. This funding boosts its financial ...
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the Company ...
Alector, Inc. has a 1-year low of $3.69 and a 1-year high of $8.90. The stock has a market capitalization of $368.22 million, a price-to-earnings ratio of -2.19 and a beta of 0.66.
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the Company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback